Mepolizumab for severe eosinophilic asthma - A one-year real life Portuguese study

Pulmonology. 2021 Nov-Dec;27(6):579-581. doi: 10.1016/j.pulmoe.2021.05.007. Epub 2021 Jul 1.

Authors

R Brás¹, M Paulino², C Varandas², C Coutinho², M I Silva², R Limão², C Costa², E Alonso², E Pedro², A Mendes²

Affiliations

¹ Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal. Electronic address: ritasabras@gmail.com.
² Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

PMID: 34219042
DOI: 10.1016/j.pulmoe.2021.05.007

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adolescent
Adult
Aged
Antibodies, Monoclonal, Humanized* / therapeutic use
Asthma* / drug therapy
Female
Humans
Male
Middle Aged
Portugal / epidemiology
Pulmonary Eosinophilia* / drug therapy
Young Adult

Substances

Antibodies, Monoclonal, Humanized
mepolizumab